Supplementum 299: Abstracts of the joint annual meeting of the Swiss Society of Cardiology (SSC), the Swiss Society for Heart and Thoracic Vascular Surgery (SSCS), the Swiss Society of Pneumology (SSP) and the Swiss Society for Thoracic Surgery (SSTS): Basel, Switzerland, June 10-12, 2026 - Posters SSC and SSCS

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Hypertrophic cardiomyopathy (n=292). Intervention: RoMa classification (RoMa II-IV) vs. RoMa I. Primary outcome: Composite of all-cause and cardiovascular death, sudden cardiac death or aborted SCD, heart failure-related hospitalization, stroke, systemic embolism, surgical myectomy, and heart transplantation (HR 3.89 to 5.37, p=<0.05).

Swiss Society of Cardiology; Swiss Society for Heart and Thoracic Vascular Surgery

doi:10.57187/5577

June 3, 2026Swiss Medical WeeklyOpen Access

Supplementum 299: Abstracts of the joint annual meeting of the Swiss Society of Cardiology (SSC), the Swiss Society for Heart and Thoracic Vascular Surgery (SSCS), the Swiss Society of Pneumology (SSP) and the Swiss Society for Thoracic Surgery (SSTS): Basel, Switzerland, June 10-12, 2026 - Posters SSC and SSCS

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does the RoMa classification predict adverse outcomes in patients with hypertrophic cardiomyopathy?

Key Points

Summarize cardiovascular and thoracic research presented at the joint annual meeting of Swiss cardiology, pneumology, and thoracic surgery societies.
Multicenter cohort and registry studies assessed diagnostic markers and clinical therapeutics across Swiss medical centers.
Key investigations analyzed mavacamten efficacy in obstructive hypertrophic cardiomyopathy (SWISS-MAVA cohort) and clinical risk prediction under tafamidis in transthyretin amyloid cardiomyopathy (SWISS-CARE registry).
In the SWISS-MAVA cohort at 52.4±21.4 weeks, 79.3% (65/82) achieved an LVOT gradient <30 mmHg and 86.6% (71/82) improved by ≥1 NYHA class with an LVOT gradient <50 mmHg.
In the SWISS-CARE registry, MACE occurred in 25% (113) of patients at median 558 days, with independent prediction by age (HR 1.31, 95%CI: 1.03-1.65, p <0.05), arterial hypertension (HR 1.61, 95%CI: 1.07-2.41, p <0.05), NT-proBNP (HR 1.31, 95%CI: 1.03-1.68, p <0.05), and moderate-to-severe tricuspid valve disease (HR 1.61, 95%CI: 1.08-2.41, p <0.05).

Study Design

Type

Cohort (n=292)

Multicenter

Yes

Structured PICO

Does the RoMa classification predict adverse outcomes in patients with hypertrophic cardiomyopathy?

P

Population

292 patients with hypertrophic cardiomyopathy (maximal left ventricular wall thickness ≥15 mm or ≥13 mm in genotype-positive individuals with LVOT obstruction), median age 51 [IQR 36-63] years, 70% male, 30% with obstructive LVOT, naïve to disease-specific therapy.

I

Intervention

RoMa classification (RoMa II-IV) based on percent predicted heart rate and oxygen pulse derived from cardiopulmonary exercise testing

C

Comparator

RoMa I classification

O

Outcome

Composite of all-cause and cardiovascular death, sudden cardiac death (SCD) or aborted SCD, heart failure-related hospitalization, stroke, systemic embolism, surgical myectomy, and heart transplantationcomposite

Main Result

Effect estimate: HR 3.89 to 5.37

p-value: p=<0.05

Implication

The RoMa classification, based on cardiopulmonary exercise testing, independently predicts long-term adverse outcomes in patients with hypertrophic cardiomyopathy.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Cardiology et al. (2026) conducted a cohort in Hypertrophic cardiomyopathy (n=292). RoMa classification (RoMa II-IV) vs. RoMa I was evaluated on Composite of all-cause and cardiovascular death, sudden cardiac death or aborted SCD, heart failure-related hospitalization, stroke, systemic embolism, surgical myectomy, and heart transplantation (HR 3.89 to 5.37, p=<0.05).

Key Points

Study Design

Structured PICO

Main Result

Implication

Abstract

Discussion

Cite This Study

Key Points

Study Design

Structured PICO

Main Result

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Swiss Medical Weekly

Keep reading

More related papers

More from Swiss Medical Weekly